Abstracts tagged "cyclosporine"

Abstract Number: 1289 • 2018 ACR/ARHP Annual Meeting
Immunosuppressant Use and Gout in the Prevalent Solid Organ Transplant Population
Andrew Milgroom¹, Mara Onita Lenco¹, Kevin Francis¹, Jeffrey D. Kent², Brian LaMoreaux³ and Brian F. Mandell⁴, ¹Trinity Partners, Waltham, MA, ²Medical Affairs, Horizon Pharma USA, Inc, Lake Forest, IL, ³Horizon Pharma USA, Inc, Lake Forest, IL, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Gout is a frequent co-morbidity of solid organ transplant (SOT). Cyclosporine (CsA) is often cited as the main cause of gout in SOT, as…
Abstract Number: 2152 • 2017 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Treatment with or without a Calcineurin Inhibitor in Resistant Inflammatory Myopathy
Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose : Patients with polymyositis (PM) and dermatomyositis (DM) refractory to glucocorticoid therapy have been treated with a variety of immunosuppressants including mycophenolate mofetil (MMF)…
Abstract Number: 2371 • 2015 ACR/ARHP Annual Meeting
The Clinical Features of Recurrent Interstitial Lung Disease in Dermatomyositis Patients with Anti- Melanoma Differentiation-Associated Gene 5 Antibody
Yuji Hosono¹, Ran Nakashima¹, Kosaku Murakami², Yoshitaka Imura², Naoichiro Yukawa², Hajime Yoshifuji², Koichiro Ohmura² and Tsuneyo Mimori², ¹Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Interstitial lung disease (ILD) is the most common cause of mortality in polymyosytis (PM) and dermatomyositis (DM). It is well known that the DM…
Abstract Number: 2473 • 2012 ACR/ARHP Annual Meeting
A Randomized Trial in New Onset Juvenile Dermatomyositis: Prednisone Versus Prednisone Plus Cyclosporine Versus Prednisone Plus Methotrexate
Nicolino Ruperto¹, Angela Pistorio², Sheila Oliveira³, Rubén J. Cuttica⁴, Angelo Ravelli¹, Michel Fischbach⁵, Stefan Hagelberg¹, Tadej Avcin⁶, Emanuel Cheuret¹, Fabrizia Corona⁷, Gerard Couillault¹, Frank Dressler¹, Valeria Gerloni¹, Gary Sterba Sr.¹, Francesco Zulian¹, Maria Teresa Apaz¹, Adriana Cespedes-Cruz¹, Rolando Cimaz¹, Fabrizio De Benedetti⁸, Pierre Quartier¹, Ricardo Russo¹, Nico Wulffraat¹, Simona Angioloni¹ and Alberto Martini⁹, ¹Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ²PRINTO, Genoa, Italy, ³Istituto Giannina Gaslini, Pediatria II, Reumatologia, Paediatric Rheumatology International Trials Organisation (PRINTO) Coordinating Center, Genoa, Italy, Genova, Italy, ⁴Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, ⁵Pediatric Rheumatology International Trials Organization (PRINTO)-Istituto Gaslini, Genova, Italy, ⁶The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, ⁷Reumatologia Pediatrica, Paediatric Department University of Milano, Milano, Italy, ⁸IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ⁹Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH
Background/Purpose: Data regarding the safety and efficacy of treatment regimens for juvenile dermatomyositis(JDM) tends to be from anecdotal, small, uncontrolled, non-randomized case series. This randomized…
Abstract Number: 277 • 2012 ACR/ARHP Annual Meeting
Dyslipidemia in Juvenile Dermatomyositis: The Role of Disease Activity
Katia T. Kozu¹, Clovis Artur Silva², Eloisa Bonfa³, Adriana M. Sallum⁴, Rosa M.R. Pereira⁵, Vilma S. Viana⁶, Eduardo F. Borba⁷ and Lucia M. A. Campos⁴, ¹Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, University of São Paulo, São Paulo, Brazil, ⁶Rheumatology Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Dyslipidemia has been infrequently investigated in pediatric population with autoimmune rheumatic diseases. However, lipid abnormalities in these diseases may occur due to multiple risk…
Abstract Number: 2655 • 2012 ACR/ARHP Annual Meeting
Rapid and Effective Response to Immunosuppression in Treating Macrophage Activation Syndrome Associated with a Heterozygous Dominant Negative Mutation in RAB27a Leading to Decreased Cytolytic Activity
Randy Q. Cron¹, Mingce Zhang², Christina J. Bemrich-Stolz² and Timothy Beukelman¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Pediatrics, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is an often fatal disorder of infancy resulting from homozygous mutations in proteins involved in cytolysis (e.g. MUNC13-4, RAB27a, Perforin 1,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].